Minerva Neurosciences Inc (OQ:NERV)
Business Focus: Bio Therapeutic Drugs
| Sector: Healthcare | Industry: Biotechnology & Medical Research |
| See Regulatory Filings on SEC | |
| Company Contact | |
| Address: | 1601 TRAPELO ROAD, SUITE 284 WALTHAM MA 02451 |
| Tel: | N/A |
| Website: | https://www.minervaneurosciences.com |
| IR: | See website |
| Key People | ||
| Remy Luthringer Executive Chairman of the Board of Directors, Chief Executive Officer | Geoffrey Race President | Frederick Ahlholm Chief Financial Officer, Senior Vice President, Secretary |
| Joseph Reilly Chief Operating Officer, Senior Vice President | Ramana Kuchibhatla Senior Vice President, Head of Research and Development | Michael Davidson Chief Medical Officer |
| Business Overview |
| Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which focused on the development and commercialization of product candidates to treat patients suffering from central nervous system (CNS) diseases. It is engaged in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and have exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson's disease. It has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of the major depressive disorder (MDD). Roluperidone is a compound that blocks serotonin, sigma, and a-adrenergic receptors that are involved in the regulation of mood, cognition, sleep, and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1), protein, for the treatment of Parkinson's disease and for other neurodegenerative disorders. |
| Financial Overview |
| For the three months ended 31 March 2024, Minerva Neurosciences Inc revenues was not reported. Net loss increased 23% to $8.6M. Higher net loss reflects Research and development - Balancing increase of 61% to $4M (expense), Non-cash interest expense for the sale increase of 14% to $2.3M (expense), Stock-based Compensation in SGA increase of 29% to $246K (expense). |
| Employees: | 9 as of Dec 31, 2023 |
| Reporting Currency: | U.S. Dollars |
| Enterprise value: | N/A |
| Annual revenue (TTM): | $0.00M as of Mar 31, 2024 |
| EBITDA (TTM): | -$24.42M as of Mar 31, 2024 |
| Net annual income (TTM): | -$31.60M as of Mar 31, 2024 |
| Free cash flow (TTM): | -$20.76M as of Mar 31, 2024 |
| Net Debt Last Fiscal Year: | N/A |
| Shares outstanding: | 6,993,406 as of Apr 12, 2024 |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.